Covalently linked complexes of HIV TAT and ENV PROTEINS
OwnerSusan W. Barnett, Indresh K. Srivastava +2inventors
InventorsSusan W. Barnett, Indresh K. Srivastava, Elaine C. Kan, Victoria Allen Sharma
Life of this patent
Estimating the term…
Abstract
Complexes of HIV Env and Tat proteins are advantageous as immunogens compared to Tat or Env alone, but they may dissociate when combined with a vaccine adjuvant. To avoid dissociation, complexes of Env and Tat are stabilized by the use of covalent cross linking. The extent of cross linking is important to the binding properties of the complexes, and so is controlled to avoid the loss of Env's ability to bind specifically to CD4 and Tat's ability to bind specifically to anti-Tat monoclonal antibodies.
Claims9
A complex comprising a HIV Env polypeptide and a HIV Tat polypeptide, wherein (i) the Env and Tat polypeptides are covalently linked, and (ii) the complex can bind specifically to CD4.
A process for preparing a complex that comprises a HIV Env polypeptide and a HIV Tat polypeptide, comprising the step of allowing Env and Tat polypeptides to interact under reaction conditions where they become covalently linked to each other without removing the Env protein's ability to bind specifically to CD4.
The complex or process of any preceding claim, wherein the Env and Tat are from HIV-1.
The complex or process of any preceding claim, wherein the Env and Tat are linked via a homobifunctional cross linker.
The complex or process of any preceding claim, wherein the Env and Tat are linked via reaction with formaldehyde or a dialdehyde.
The complex or process of any preceding claim, wherein the Env and Tat are present at essentially a 1:1 molar ratio.
Dependencies are inferred from the claim text.